Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Crescent Biopharma, Inc. (CBIO) operate in?
Crescent Biopharma, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Crescent Biopharma, Inc. (CBIO) current stock price?
As of the latest data, Crescent Biopharma, Inc. stock price is $16.29, with a previous close of $16.69. Crescent Biopharma, Inc. lost -$0.41 in the last trading session, representing a -2.43% loss.
What is Crescent Biopharma, Inc. (CBIO) current market capitalization?
Crescent Biopharma, Inc. market cap is approximately 604.89 million.
What is Crescent Biopharma, Inc. (CBIO) Earnings Per Share (EPS)?
The trailing EPS is -$0.14, and the forward EPS is -$2.98.
What is Crescent Biopharma, Inc. (CBIO) EBITDA?
Crescent Biopharma, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -26.36 million.
Does Crescent Biopharma, Inc. (CBIO) pay dividends?
Yes. Crescent Biopharma, Inc. pays annual dividends with an annualized yield of 1.47% and an estimated annual payout of $0.24 per share.
What is Crescent Biopharma, Inc. (CBIO) beta (volatility) score?
Crescent Biopharma, Inc. has a beta of 2.741, indicating very high volatility compared to the market.
